Solubilized cosmetic composition comprising glycolipids and lysophospholipids

Abstract

Solubilizing cosmetic composition containing glycolipid and lysophospholipid. The present invention relates to a solubilizing composition containing micelles formed of a glycolipid and a lysophospholipid. The solubilizing composition according to the present invention has an effect superior to that of a conventional solubilizing composition in terms of moisturization, improvement of skin barrier, preservation stability, and can have a completely transparent dosage form.

Description

Technical Field

[0001] This invention relates to a solubilized cosmetic composition comprising glycolipids and lysophospholipids. Background Technology

[0002] The skin barrier, which protects against the penetration of harmful external substances, is primarily located in the stratum corneum of the epidermis. This stratum corneum protects the body from external physical damage and chemical aggressors, and prevents the evaporation of moisture from the body, thus preventing dry skin. Research on the lipid composition of the stratum corneum has been active since the beginning of research. Elias et al. reported that the lamellar structure formed by lipid components within the stratum corneum is the root of skin barrier function (J. Invest. Dermatol. 69:535-546, 1977). Furthermore, although variations exist depending on experimental methods and the location of the lipids in the skin tissue, it is generally known that intercellular lipids consist of approximately 50% ceramides, 20–25% cholesterol, 20–25% free fatty acids, 10% cholesterol esters, 1–2% cholesterol sulfate, and a small amount of phospholipids.

[0003] To apply this skin barrier function to cosmetics, many researchers have developed various dosage forms, such as liquid crystal emulsions, by mimicking the skin barrier function. The main purpose of these dosage forms is to stably incorporate intercellular lipids, a key component of the skin barrier function, with a focus on ceramides, cholesterol, and phospholipids. Since ceramides and cholesterol were identified as major components of intercellular lipids, key components of the skin barrier, and also potent moisturizing ingredients, their stability has been extensively studied. However, they exhibit gelling characteristics over time when used in general emulsion formulations. Therefore, in most cosmetic formulations, they are used in very small quantities or prepared as stable raw materials through separate pretreatment using high-pressure emulsification methods (such as microfluidizers) before use. However, this high-pressure emulsification method requires specialized equipment, is cumbersome, and increases costs, thus it cannot be considered a preferred method. To overcome this problem, many researchers have long been researching the solubilization of ceramides or the fabrication of nanoliposomes through high-pressure emulsification.

[0004] For example, Korean Patent Application No. 10-2003-0062910, "Cosmetic Composition for Skin Irritation Relief Containing Nanoliposomes with Intercellular Lipid Components," and Korean Patent Application No. 10-2009-0132670, "Vasculents Containing Self-Emulsifying Nanoliposomes / Multilayer Liquid Crystals and Their Preparation Method and Use," both use high-pressure emulsification to prepare nanoliposomes to stabilize intercellular lipid components containing ceramides, cholesterol, and phospholipids. However, this method requires additional equipment called a high-pressure emulsifier, which incurs additional costs and time, and therefore cannot be considered a preferred method.

[0005] In addition, Korean Patent Registration Nos. 10-1572216, 10-0654846, and 10-1529480 disclose a method for preparing a nanoemulsion solubilizing composition in liposome form by combining ceramides and phospholipids with fatty acids such as cholesterol.

[0006] The phospholipid solubilization techniques described above, which utilize ceramides and lecithin, allow particles to form in bilayers, such as liposomes. Therefore, they have limitations in preparing solubilized forms that are completely transparent.

[0007] Existing technical documents

[0008] Patent documents

[0009] 1. Korean Patent Application No. 10-2003-0062910

[0010] 2. Korean Patent Application No. 10-2009-0132670

[0011] 3. Korean Patent Registration No. 10-1572216

[0012] 4. Korean Patent Registration No. 10-0654846

[0013] 5. Korean Patent Registration No. 10-1529480 Summary of the Invention

[0014] The problem to be solved

[0015] The purpose of this invention is to provide a solubilizing composition that has superior effects on moisturizing, improving the skin barrier, and maintaining stability compared to existing solubilizing compositions, and has a completely transparent dosage form.

[0016] Solution to the problem

[0017] The present invention provides a solubilizing composition comprising micelles formed from glycolipids and lysophospholipids.

[0018] This invention provides the use of a solubilizing composition comprising micelles formed from glycolipids and lysophospholipids in the preparation of cosmetics.

[0019] The effects of the invention

[0020] The solubilizing composition according to the present invention has superior effects on moisturizing, improving skin barrier, and preservation stability compared to existing solubilizing compositions, and can be in a completely transparent dosage form.

[0021] In addition, micelles are composed of glycolipids and lysophospholipids, which are components of intercellular lipids, thus enabling the solubilization of poorly soluble substances useful in cosmetics without the use of surfactants that irritate the skin. Attached Figure Description

[0022] Figure 1 These are photographs of the dosage forms (compositions) prepared according to Example 2 and Comparative Example 1 of the present invention.

[0023] Figure 2 The results of measuring micelle particle size in the compositions of Example 2 and Comparative Example 2 according to the present invention are shown. Detailed Implementation

[0024] This invention relates to a solubilizing composition comprising micelles formed from glycolipids and lysophospholipids.

[0025] This invention relates to the use of a solubilizing composition comprising micelles formed from glycolipids and lysophospholipids in the preparation of cosmetics.

[0026] The following describes the structure of the present invention in detail.

[0027] In this invention, micelles are generally defined as thermodynamically stable and uniform spherical structures formed by low molecular weight amphiphilic substances (e.g., having both hydrophilic and hydrophobic groups).

[0028] Amphiphilic substances commonly used to form micelles include surfactants, and also polymers with specific molecular structures. When such amphiphilic substances are dissolved in water or other solvents, they tend to exhibit the following behavior: due to thermodynamic stability, the hydrophilic groups hydrate on the solvent surface and align towards the water, while the hydrophobic chains align towards the outer side of the surface. If the concentration continues to increase, the surface of the solution becomes saturated with the surfactant, the surface tension no longer decreases, and in aqueous solutions, the hydrophilic groups of the surfactant aggregate outwards while the hydrophobic chains aggregate inwards, thus forming spherical polymers, i.e., micelles.

[0029] In this invention, micelles can be formed from glycolipids and lysophospholipids, which are components of intercellular lipids.

[0030] The aforementioned glycolipids and lysophospholipids have the characteristics of amphiphilic molecules (i.e., they have both hydrophilic and hydrophobic groups in one molecule). Therefore, below a certain concentration, they function similarly to surfactants. However, if the concentration exceeds a certain level, they form micelles and may move in the form of floating matter.

[0031] In this invention, glycolipids refer to substances in which carbohydrates are bound to lipids via glycosidic bonds. Lipids with attached glycans are almost entirely found on the outer lipid bilayer of the cell membrane in eukaryotic cells and exist in a hydrophilic environment due to the polar groups present in the carbohydrates. These glycolipids play a role in maintaining cell membrane stability.

[0032] In one specific example, there is no particular limitation on the type of glycolipid, and it may include one or more of the group consisting of trehalose lipid, rhamnolipid, sophorolipid, mannoerythritol lipid, glyceroglycolipid, and sphingoglycolipid.

[0033] In one specific example, the content of glycolipids is not particularly limited, and can be 0.01 to 1.5 parts by weight or 0.1 to 0.9 parts by weight relative to 100 parts by weight of the total solubilized composition. Within the above range, dosage form-stable micelles and solubilized compositions can be prepared.

[0034] In this invention, lysophospholipids are known substances that break down cell walls or induce the fusion of erythrocytes or liposomes. Lysophospholipids approaching the cell membrane from the outside initially form a monolayer on the outer surface of the cell membrane, adsorbing and gradually reversing the cell membrane structure. Therefore, a localized phase separation effect is produced within the homogeneous lipid bilayer, thereby increasing the overall permeability of the cell membrane. This effect can vary depending on the hydrocarbon chain length and the degree of hydrogenation of the carbon chain in the lysophospholipid molecule.

[0035] On the other hand, lysophospholipids have a conical overall structure, but as a structure in which the area occupied by the polar head of a carbon chain is larger than that of the tail, they have a structure opposite to that of DOPE. Therefore, when lysophospholipids are dispersed in water, they can form micelles above the critical micelle formation concentration (CMC).

[0036] The aforementioned lysophospholipids have a conical structure that improves skin membrane compatibility, thereby enhancing the skin delivery rate of physiologically active substances. There are no particular limitations on the type of lysophospholipid, and lysophospholipids commonly used in cosmetic compositions can be used. For example, one or more of the following groups can be used: soy-derived lysophospholipids, soy-derived hydrogenated lysophospholipids, egg yolk-derived lysophospholipids, egg yolk-derived hydrogenated lysophospholipids, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylserine, hydrogenated lysophosphatidylcholine, and hydrogenated lysophosphatidylcholine.

[0037] In one specific example, the content of lysophospholipids is not particularly limited, and may be 0.01 to 1.0 parts by weight or 0.1 to 0.3 parts by weight relative to 100 parts by weight of the total solubilizing composition. Within the above range, dosage form-stable micelles and solubilizing compositions can be prepared.

[0038] In this invention, the mono-layer micelles are formed from glycolipids and lysophospholipids.

[0039] Phospholipids, such as phosphatidylcholine and phosphatidylethanolamine, act as surfactants and possess two hydrophobic chains, resulting in a near-cylindrical structure. Surfactants with a CPP of 1 or higher can only self-assemble into bilayer liposomes, thus increasing the overall particle size. Furthermore, while bilayer sheet structures like liposomes are generally suitable for creams and similar formulations, their use in solubilizers like lotions is limited due to opacity issues caused by floating.

[0040] In this invention, a lysophospholipid is used, wherein the number of hydrophobic tails of the phospholipid is adjusted to one. Since the aforementioned lysophospholipid is structurally close to a cone shape, it can self-assemble into a monolayer of spherical micelles. Therefore, the composition of this invention maintains the micelle structure, and these micelles can be stably maintained in solubilizers such as lotions, and can provide a transparent cosmetic.

[0041] In particular, in this invention, lysophospholipids and glycolipids form micelles together. Since the hydrophobic groups of phospholipids are formed by chains of a certain length, the hydrophobic portion of liposomes or micelles formed solely from phospholipids approximates a neatly arranged gel phase. Conversely, when mixed-micelles are formed with glycolipids, as the hydrophobic portion of the glycolipids reduces the long-range order of the phospholipids and increases mobility, the hydrophobic core approximates a fluid phase. As a result, the mixed-micelle particles become more stable in the water-in-oil (O / W) phase. Furthermore, due to this increased disorder of the hydrophobic groups, the increased micelle curvature deformation (depending on the type and ratio of lysophospholipids / glycolipids) leads to changes in particle size.

[0042] In one specific example, the average particle size of the micelles can be 20 to 200 nm or 30 to 70 nm. Transparent and stable compositions can be prepared within these particle size ranges. In this case, transparency can mean that the particle size is about one-quarter of the visible light range. Specifically, the micelles prepared in Example 2 of the present invention have an average particle size of 45.61 nm, which is below 100 nm (the Brownian motion region in colloidal aqueous solutions), so the particles will not settle due to gravity. Furthermore, the particle size is related to the transparency of the aqueous solution, and the composition appears transparent within the particle size range of the present invention, while if the particle size exceeds the aforementioned range, the composition becomes opaque due to light scattering. That is, the compositions of the present invention do not exhibit the Tyndall effect, and in this case, stability is generally excellent. The Tyndall effect refers to the phenomenon where the solution becomes turbid or bluish due to light scattering between particles when strongly incident light.

[0043] In one specific example, the micelle content is not particularly limited and can be from 0.1 to 15% by weight relative to the total solubilized composition.

[0044] In addition to the above-mentioned components, the solubilizing composition according to the present invention may further contain polyols.

[0045] Polyols, specifically diols (i.e., glycolic acid diols), are compounds with two hydroxyl groups (-OH) in their hydrocarbon chains, and function in compositions in various ways, such as solvents, conditioning agents, and humectants. In this invention, diols that meet specific hydrocarbon length requirements are used, thereby imparting enhanced stability.

[0046] That is, the composition of the present invention contains polyols, thus the micelles formed are stabilized, thereby not only maintaining the stability of the dosage form for a longer period of time, but also helping to prevent the growth of sheet structures.

[0047] In one specific example, there is no particular limitation on the type of polyol, and it can be one or more selected from the group consisting of propylene glycol, dipropylene glycol, butanediol, 1,3-butanediol, pentanediol, 2-methyl-2,4-pentanediol (Hexylene Glycol) and hexanediol.

[0048] In one specific example, the content of the polyol is not particularly limited, and may be 2 to 20 parts by weight or 3 to 10 parts by weight relative to 100 parts by weight of the total solubilized composition.

[0049] The solubilizing composition according to the invention may further comprise oils, fragrances, or mixtures thereof. The aforementioned oils, fragrances, or mixtures thereof can be trapped in micelles. Here, fragrance does not refer solely to simply aromatic components, but rather to cosmetic fragrances or corresponding fragrance substitutes.

[0050] In one specific example, there are no particular restrictions on the types of oils and fragrances, and more than one selected from the group consisting of ester-based synthetic oils, silicone oils (e.g., polydimethylsiloxane and cyclic polymethylsiloxane oils), animal and vegetable oils (e.g., jojoba oil and squalane), and synthetic and natural fragrances can be used. Furthermore, raw materials that are known in the art as poorly soluble substances useful in cosmetics can be selected.

[0051] In one specific example, the content of oil, fragrance, or mixture thereof may be from 0.01 to 1 part by weight relative to 100 parts by weight of the total solubilizing composition.

[0052] In addition to the above-mentioned components, the solubilizing composition according to the present invention may also contain components commonly used in solubilizing types, and for example, may contain conventional additives such as stabilizers, solubilizers, vitamins, pigments, etc.

[0053] In addition, the present invention relates to a method for preparing the above-mentioned solubilizing composition.

[0054] According to the solubilizing composition of the present invention, glycolipids and lysophospholipids constituting micelles are heated in a polyol to about 40 to 70°C, preferably about 50 to 60°C, and mixed and dissolved to prepare a solubilizing raw material. Subsequently, the above-mentioned solubilizing composition can be prepared by mixing and stirring the solubilizing raw material in an aqueous phase raw material of purified water or an aqueous phase raw material prepared by mixing and dissolving purified water, a polyol, etc.

[0055] In addition, the present invention relates to a cosmetic composition comprising the above-described solubilizing composition.

[0056] In this invention, cosmetic compositions, by including the solubilizing composition according to the invention, can also be prepared into any dosage form commonly prepared in the art, and can be formulated into, for example, solutions, suspensions, emulsions, ointments, gels, creams, lotions, powders, soaps, oils, powder foundations, emulsion foundations, wax foundations, sprays, etc. More specifically, they can be formulated into toners, lotions, softening lotions, nourishing toners, nourishing creams, massage creams, serums, eye creams, mists, cleansing creams, cleansing foams, cleansing waters, masks, sprays, or powders. When the dosage form of the above compositions is an ointment, cream, or gel, animal oils, vegetable oils, waxes, paraffin wax, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide, etc., can be used as carrier components. When the above composition is in the form of a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier component. In particular, when it is a spray, a propellant such as chlorofluorocarbon, propane / butane, or dimethyl ether can be further included. When the above composition is in the form of a solution or emulsion, a solvent, solubilizer, or emulsifier can be used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butanediol oil, aliphatic glycerides, polyethylene glycol, or fatty acid esters of dehydrated sorbitol. In addition, when the above composition is in the form of a suspension, liquid diluents (e.g., water, ethanol, or propylene glycol), suspending agents (e.g., ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene dehydrated sorbitol ester), microcrystalline cellulose, aluminum hydroxide, bentonite, agar, or tragacanth gum can be used as the carrier component.

[0057] The ingredients described above in the cosmetic composition according to the present invention are preferably included in the cosmetic composition of the present invention within a range not exceeding the maximum usage specified in the "Cosmetic Safety Technical Specifications" stipulated by the Chinese government.

[0058] The present invention will now be described in detail through embodiments. These embodiments are merely illustrative and the scope of the invention is not limited to them. These embodiments are provided to fully disclose the invention and to clearly explain the scope of the invention to those skilled in the art, and the invention is defined only by the scope of the claims.

[0059] Example

[0060] Examples 1 to 12 and Comparative Examples 1 to 4

[0061] Compositions comprising micelles composed of glycolipids and lysophospholipids (Examples) and compositions not comprising micelles composed of glycolipids and lysophospholipids (Comparative Examples) were prepared with the following compositions and contents (Tables 1 and 2).

[0062] Specifically, phase A is heated to 50 to 60°C and mixed to dissolve, then slowly added to phase B while stirring, and then cooled to prepare each composition (dosage form).

[0063] [Table 1]

[0064]

[0065] [Table 2]

[0066]

[0067] Experimental Example 1. Confirming the transparency of the dosage form

[0068] In this invention, Figure 1 These are photographs of the dosage forms (compositions) prepared according to Example 2 and Comparative Example 1 of the present invention.

[0069] As above Figure 1 As shown, it can be confirmed that the dosage form of Example 2 (left) is transparent compared to the dosage form of Comparative Example 1 (right), which does not contain glycolipids.

[0070] Experimental Example 2. Measuring Dosage Form Stability

[0071] The stability tests of the dosage forms (compositions) according to the embodiments and comparative examples of the present invention were conducted by the following methods.

[0072] The stability of the dosage form is evaluated according to the following criteria.

[0073] - Conditions: 25℃ / Freezing / Thawing (temperature variation)

[0074] - Duration: 1 day / 1 month

[0075] - Judgment: ○ (Stable) / △ (Relatively Stable) / X (Poor)

[0076] Stable: Transparent with no floating or sediment found.

[0077] Relatively stable: with a bluish transparency, no floating matter or sediment was found.

[0078] Poor: Severe suspension or presence of floating matter and sediment.

[0079] Among the measurements described above, the freeze-thaw stability test (FTS) is one of the representative evaluation methods implemented to ensure the stability and reliability of cosmetic compositions. Furthermore, because the experimental conditions for this evaluation method are relatively stringent, compositions with good FTS cycle stability results can be considered to have high reliability and commercial viability when commercialized.

[0080] In the above-mentioned method for evaluating freeze-thaw stability, the composition prepared by the above method is placed in a transparent container and sealed, stored in a chamber at -20°C for 24 hours, and then stored at room temperature for 24 hours and the thawed state is observed.

[0081] (1) Measure the dosage form stability of the composition (Example) containing micelles composed of glycolipids and lysophospholipids.

[0082] The dosage form stability of the compositions of Examples 1 to 8, which contain micelles composed of glycolipids and lysophospholipids, was measured.

[0083] At this time, the measurement temperature is 25℃, and the measurement period is 1 day / 1 month.

[0084] The results are shown in Table 3 below.

[0085] [Table 3]

[0086]

[0087] As shown in Table 3 above, it can be confirmed that the compositions of the examples prepared from 0.1 to 0.9 wt% glycolipids and 0.1 to 0.6 wt% lysophospholipids have excellent stability after 1 day.

[0088] In particular, measurements showed that when the concentration of glycolipids was 0.1 to 0.6% by weight and the concentration of lysophospholipids was 0.1 to 0.6% by weight, the dosage form exhibited excellent stability at 1 day and 1 month, while Comparative Example 1, which did not contain glycolipids, showed low dosage form stability at 1 month. Preferably, the concentration of glycolipids is 3 to 5 times that of the solubilized flavoring, and the concentration of lysophospholipids is equal to or less than that of glycolipids, which provides excellent dosage form stability.

[0089] (2) Measure the formulation stability according to the type of glycol compound.

[0090] The dosage form stability of compositions prepared according to the type of diol compound in the embodiments of the present invention was measured.

[0091] At this time, the measurement conditions are freezing / thawing (temperature change), and the number of evaluations is 1, 2, and 3.

[0092] The results are shown in Table 4 below.

[0093] [Table 4]

[0094]

[0095] As shown in Table 4 above, it can be confirmed that the composition further containing polyol compounds (Examples 2, 9 to 11) has improved dosage form stability compared to the case without polyol compounds (Example 12).

[0096] In particular, it can be confirmed that when butanediol is included as a polyol, it can impart superior stability under harsh freezing / thawing conditions.

[0097] (3) Measure the dosage form stability of the composition that does not contain lysophospholipids and / or glycolipids.

[0098] Comparative Example 2 is a single phospholipid composition, and Comparative Example 3 is a single lysophospholipid composition. Additionally, Comparative Example 4 is a composition using a PEG surfactant but without glycolipids and lysophospholipids.

[0099] In this experimental example, the dosage form stability of the compositions according to the comparative examples described above was evaluated.

[0100] At this time, measurements were taken at a temperature of 25°C for 1 day / 1 month. Additionally, evaluations were conducted 1, 2, and 3 times by freezing / thawing (temperature change).

[0101] The results are shown in Table 5 below.

[0102] [Table 5]

[0103]

[0104] As shown in Table 5 above, Comparative Examples 2 to 3 exhibited lower dosage form stability compared to the Examples. This is because, compared to the Comparative Examples, the micelles prepared according to the Examples formed smaller micelles, thus exhibiting a significantly reduced average particle size, thereby improving the stability of the composition.

[0105] Comparative Example 4, which uses a PEG surfactant, exhibits similar formulation stability to the examples. However, there is a concern that the PEG surfactant may cause skin irritation.

[0106] Experiment Example 3. Measuring Particle Size

[0107] In the compositions of Examples 2 and Comparative Examples 2 to 4, the particle size of the micelles was measured.

[0108] The above measurements were performed using a zeta-sizer to determine the average particle size (z-average) without dilution.

[0109] The results are shown in Table 6 and Figure 2 middle.

[0110] [Table 6]

[0111]

[0112] As shown in Table 6 above and Figure 2 As shown, it can be confirmed that, compared with the comparative example, the micelles prepared according to the examples form smaller micelles, and therefore have a significantly reduced average particle size. Therefore, the compositions of the examples exhibit excellent dosage form stability.

[0113] Experiment Example 4. Evaluating Water Retention Capacity

[0114] The moisture retention capacity of the compositions prepared in Example 2 and Comparative Example 4 was evaluated in six subjects.

[0115] Moisture retention capacity was measured using a method that measures the electrical conductivity of the skin surface using a SKICON-200 (IBS).

[0116] In a constant temperature and humidity chamber maintaining 25℃ and 40% relative humidity, every 16cm 2 After applying 0.03g of the sample to the skin, the resistivity (moisture loss) was measured over time. However, the average microseconds (µs) before applying the sample were set to 50.

[0117] The results are shown in Table 7 below.

[0118] [Table 7]

[0119]

[0120] The higher the measured value, the higher the moisture retention capacity.

[0121] As shown in Table 7 above, it can be confirmed that, compared with the comparative example, the micelle-containing composition prepared according to the examples has excellent moisture retention over time.

[0122] Experimental Example 5. Evaluation of the skin barrier improvement effect

[0123] The skin barrier improvement effect of the compositions prepared in Example 2 and Comparative Example 4 was evaluated in 5 subjects.

[0124] The improvement in skin barrier function was measured using a Tewameter™-300 (C+K electronic) to measure the amount of moisture evaporation from the skin surface. After treatment with a 1% SLS solution to induce arbitrary skin damage, the solution was applied once daily at 16 cm intervals. 2After applying 0.03 g of the sample to the skin, the skin moisture evaporation (skin barrier recovery rate) was measured at 1 day and 4 days later in a constant temperature and humidity chamber maintained at 25°C and 40% relative humidity.

[0125] The results are shown in Table 8 below.

[0126] [Table 8]

[0127]

[0128] As shown in Table 8, it can be confirmed that, compared with the comparative examples, the micelle-containing compositions prepared according to the examples have excellent skin barrier improvement effects over time.

Claims

1. A solubilizing composition comprising a monolayer of micelles formed from glycolipids and lysophospholipids, and a polyol. in, The glycolipid comprises 0.1 to 0.6 parts by weight relative to 100 parts by weight of the total solubilizing composition. The lysophosphatidylcholine comprises 0.1 to 0.6 parts by weight of the lysophosphatidylcholine relative to 100 parts by weight of the total solubilizing composition. The concentration of the lysophospholipid is equal to or less than the concentration of the glycolipid.

2. The solubilizing composition according to claim 1, wherein, The average particle size of the micelles ranges from 20 to 200 nm.

3. The solubilizing composition according to claim 1, wherein, The polyol is selected from one or more of the group consisting of propylene glycol, dipropylene glycol, butanediol, pentanediol, and hexanediol.

4. The solubilizing composition according to claim 3, wherein, The butanediol is 1,3-butanediol, and the hexanediol is 2-methyl-2,4-pentanediol.

5. The solubilizing composition according to claim 1, wherein, The polyol content is 2 to 20 parts by weight relative to 100 parts by weight of the total solubilized composition.

6. The solubilizing composition of claim 1, wherein, Micelles capture oils, fragrances, or mixtures thereof.

Images